Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer.

Jun Ho Yi, In-Gu Do, Jiryeon Jang, Seung Tae Kim, Kyoung-Mee Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Jeeyun Lee

Journal: Scientific reports 2015;4():7592

PMID: 25534230

Free Full Text on Nature Publishing Group View on PubMed

Abstract

To investigate the prognostic role of the estrogen receptor (ER) in gastric cancer (GC) patients, tumor tissues from 932 patients with advanced GC were assessed for ER expression using immunohistochemistry, and their clinicopathologic features were evaluated. Forty patients (4.3%) had ER expression and they were more frequently associated with diffuse type gastric cancer and shorter disease free survival. Furthermore, we carried out in vitro analysis to evaluate the effect of ER modulation on the proliferation of GC cell lines. Estradiol enhanced proliferation of ER positive GC cells while it did not show any effect on ER negative GC cells. When ER was inhibited by fulvestrant and ER siRNA, estradiol-induced proliferation of ER positive GC cell was suppressed. Paclitaxel showed synergistic anti-proliferative impacts with fulvestrant. Suppressing ER by fulvestrant, paclitaxel and ER siRNA showed increased expression of E-cadherin, which is a crucial factor in diffuse-type carcinogenesis.

Address: 1] Division of Hematology-Oncology, Department of Medicine, Hanyang University Hospital, Seoul, Korea [2] Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.; Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.; Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

DOI: 10.1038/srep07592

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/stomachcancer.html

Other Literature Sources:

https://scite.ai/reports/25534230

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-3321

MeSH Terms: Adult, Aged, Antineoplastic Agents, Hormonal, Antineoplastic Agents, Phytogenic, Cell Line, Tumor, Disease-Free Survival, Estradiol, Female, Fulvestrant, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Male, Middle Aged, Paclitaxel, Receptors, Estrogen, Stomach Neoplasms, Survival Rate